Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB, NSCLC, NSCLC, Stage IIIA, NSCLC Stage IIIB
Conditions
Keywords
Immunonutrition, Radiotherapy, Unresectable, Stage IIIA-B, Lung cancer, Radiation oncology, Thoracic oncology, Epidemiology, Nutrition
Brief summary
The purpose of this study is to assess whether either or both nutrition supplements (Impact® Advanced Recovery or Boost® High Protein) ingested prior to and during concurrent chemoradiotherapy decreases toxic side effects of treatment in Stage IIIA-B non-small cell lung cancer.
Interventions
RADIATIONRadiation Therapy
Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
DIETARY_SUPPLEMENTImpact® Advanced Recovery
The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
DIETARY_SUPPLEMENTBoost® High Protein
The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
DRUGChemotherapy
Standard of Care: Chemotherapy as already planned for each participant.
OTHERQuality of life (EORTC-QLQ-30)
Participants will undergo pre- and post-treatment assessments.
OTHEREvaluation of Cognitive Function (FACT-Cog, v. 3.0)
Participants will undergo pre- and post-treatment assessments.
OTHERMindfulness Questionnaire (FFMQ)
Participants will undergo pre- and post-treatment assessments.
Sponsors
H. Lee Moffitt Cancer Center and Research Institute
Nestle Health Science
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)
Masking description
Randomized open-label, medical and radiation oncologist-blinded.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients will be recruited from the Moffitt Cancer Center Thoracic Oncology Outpatient Clinic when identified by a thoracic oncologist that the patient will undergo all of their chemoradiotherapy at Moffitt. * Men and women ≥18 years of age. * Diagnosed with unresectable stage IIIA or IIIB non-small cell lung cancer. * Patients plan to undergo all cancer treatment at Moffitt Cancer Center with definitive concurrent chemotherapy and radiotherapy. * No prior treatment of NSCLC. * Able to provide informed consent. * Performance status 0, 1 or 2. * Life expectancy \>3 months. * No esophagitis within 90 days.
Exclusion criteria
* Mental incompetence or chronic psychiatric disease. * Incarcerated individuals. * Use of antibiotics or probiotic supplements within one month of chemoradiotherapy. * Allergy to any of the components of Impact® Advanced Recovery or Boost® High Protein. * Pregnant female or breast-feeding. Any female patient \<45 years old not using appropriate contraceptive measures during the treatment. * Sepsis or active infection. * Chronic renal failure stage IV (requiring protein restriction) or stage V requiring dialysis. * Malnutrition defined as BMI \<16. * Inflammatory bowel disease (ulcerative colitis or Crohn's disease). * Severe hepatic dysfunction (baseline prothrombin time off any anticoagulation of international normalized ratio (INR) \>1.8). * Significant digestive disease with nausea, vomiting or diarrhea, NCI Grade \>1. * Use of IL-6 inhibitors (tocilizumab or siltuximab) within last 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment Related Adverse Events Per Study Arm | Up to 48 months | Overall toxicity from therapy as assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) v. 5.0 that directly correlates with toxicity from concurrent chemoradiotherapy. Based on another randomized trial using pretreatment immunonutrition, investigators want to see if this nutritional intervention will likely decrease overall chemoradiotherapy related toxicity. All toxicity and adverse events (CTCAE v.5.0) will be assessed weekly and attributed by the treating radiation oncologist and entered into the clinical trials management database OnCore for later statistical analysis. Differences in toxicity events at the end of the study in participants receiving Impact® and those receiving Boost® will be compared using two-sample t-test. |
| Change in Plasma Levels of IL-6 Per Study Arm | Up to 48 months | Measurement of the marked change of IL-6 that directly correlates with toxicity from concurrent chemoradiotherapy. Multiplex immunoassay will be used to determine the plasma levels of IL-6 in pg/ml as a continuous variable. Two-sample t-test for change in IL-6 at the last visit from the baseline will be compared between the two arms. Kolmogorove-Smirnov and Jarque-Bera tests will be performed to test for normality assumption on the primary endpoints prior to t-test analysis. If either test indicates a violation of the normality assumption, investigators will use an appropriate rank-based Wilcoxon rank-sum test instead of t-test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) 9OS) | Up to 2 years | Overall survival (OS) defined as the length of time interval between the date of cancer treatment completion and the date of death due to any cause. Kaplan-Meier curves will be estimated for each arm. Log-rank test will be performed to examine the effect of Impact® vs. Boost® on measures of OS. |
| Progression-free Survival (PFS) | Up to 2 years | Progression-free survival (PFS) will be assessed using the length of time interval from the cancer treatment completion to the earlier of the first documentation of disease progression or death from any cause. Kaplan-Meier curves will be estimated for each arm. Log-rank test will be performed to examine the effect of Impact® vs. Boost® on measures of PFS. |
| Rate of Treatment Changes or Interruptions Per Study Arm | Up to 2 years | Treatment interruptions, chemotherapy dose reduction or hospitalizations secondary to toxicity. |
| Rate of Participant Regimen Compliance Per Study Arm | Up to 2 years | Rate of participant compliance, with immunonutrition regimen, according to participant diaries. Each participant will complete a compliance diary noting when each carton/bottle of the study agent is drunk and the card will be collected by the Study Coordinator at on treatment clinic visits (OTV) prior to receiving the new batch of study or control supplements. |
Countries
United States
Outcome results
None listed